NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia

Progress in Brain Research

Volumn 179, Issue C, 2009, Pages 51-58

  Ramsey, Amy J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Behavioral pharmacology; Glutamate; NMDA receptor; Pharmacology; Physiology

Indexed keywords

GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NR1 NMDA RECEPTOR;

ANIMAL; BRAIN LEVEL; DOWN REGULATION; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; MUTATION; REVIEW; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

ANIMALS; BRAIN CHEMISTRY; DOWN-REGULATION; GLUTAMIC ACID; MICE; MICE, KNOCKOUT; MUTATION; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 77953375072     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/S0079-6123(09)17906-2     Document Type: Article

References (47)

1. Basu, A. C., Tsai, G. E., Ma, C. L., Ehmsen, J. T., Mustafa, A. K., Han, L., et al. (2009). Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Molecular Psychiatry, 14(7), 719-727.
2. Bickel, S., & Javitt, D. C. (2009). Neurophysiological and neurochemical animal models of schizophrenia: Focus on glutamate. Behavioral Brain Research, 204(2), 352-362.
3. Bickel, S., Lipp, H. P., & Umbricht, D. (2007). Impaired attentional modulation of auditory evoked potentials in Nmethyl-d-aspartate NR1 hypomorphic mice. Genes, Brain and Behavior, 6(6), 558-568.
4. Bickel, S., Lipp, H. P., & Umbricht, D. (2008). Early auditory sensory processing deficits in mouse mutants with reduced NMDA receptor function.. Neuropsychopharmacology, 33 (7), 1680-1689.
5. Coyle, J. T. (2006). Substance use disorders and schizophrenia: A question of shared glutamatergic mechanisms. Neurotoxicity Research, 10(3), 221-233.
6. Coyle, J. T., Tsai, G., & Goff, D. C. (2002). Ionotropic glutamate receptors as therapeutic targets in schizophrenia.. Current Drug Targets: CNS and Neurological Disorders, 1 (2), 183-189.
7. Duncan, G. E., Inada, K., Farrington, J. S., Koller, B. H., & Moy, S. S. (2009). Neural activation deficits in a mouse genetic model of NMDA receptor hypofunction in tests of social aggression and swim stress. Brain Research, 1265, 186-195.
8. Duncan, G. E., Moy, S. S., Lieberman, J. A., & Koller, B. H. (2006). Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction. Pharmacology Biochemistry and Behavior, 85(3), 481-491.
9. Duncan, G. E., Moy, S. S., Perez, A., Eddy, D. M., Zinzow, W. M., Lieberman, J. A., et al. (2004). Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behavioral Brain Research, 153(2), 507-519.
10. Duncan, G., Miyamoto, S., Gu, H., Lieberman, J., Koller, B., & Snouwaert, J. (2002). Alterations in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function. Brain Research, 951(2), 166-176.
11. Dzirasa, K., Ramsey, A. J., Takahashi, D. Y., Stapleton, J., Potes, J. M., Williams, J. K., et al. (2009). Hyperdopaminergia and NMDA receptor hypofunction disrupt neural phase signaling. Journal of Neuroscience, 29(25), 8215-8224.
12. Forrest, D., Yuzaki, M., Soares, H. D., Ng, L., Luk, D. C., Sheng, M., et al. (1994). Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death.. Neuron, 13(2), 325-338.
13. Fradley, R. L., O'Meara, G. F., Newman, R. J., Andrieux, A., Job, D., & Reynolds, D. S. (2005). STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behavioral Brain Research, 163(2), 257-264.
14. Gao, X. M., Sakai, K., Roberts, R. C., Conley, R. R., Dean, B., & Tamminga, C. A. (2000). Ionotropic glutamate receptors and expression of N-methyl-d-aspartate receptor subunits in subregions of human hippocampus: Effects of schizophrenia. American Journal of Psychiatry, 157(7), 1141-1149.
15. Halene T. B., Ehrlichman R. S., Liang Y., Christian E. P., Jonak G. J., Gur T. L., et al. (2009). Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia. Genes, Brain and Behavior, Epub ahead of print.
16. Han, L., Picker, J. D., Schaevitz, L. R., Tsai, G., Feng, J., Jiang, Z., et al. (2009). Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II.. Synapse, 63(8), 625-635.
17. Harrison, P. J., & Weinberger, D. R. (2005). Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Molecular Psychiatry, 10(1), 40-68.
18. Huh, K. H., & Wenthold, R. J. (1999). Turnover analysis of glutamate receptors identifies a rapidly degraded pool of the N-methyl-d-aspartate receptor subunit, NR1, in cultured cerebellar granule cells. Journal of Biological Chemistry, 274 (1), 151-157.
19. Inta D., Monyer H., Sprengel R., Meyer-Lindenberg A., Gass P. (2009). Mice with genetically altered glutamate receptors as models of schizophrenia: A comprehensive review. Neuroscience and Biobehavioral Reviews, August 3, Epub ahead of print.
20. International Schizophrenia Consortium,, Purcell, S. M., Wray, N. R., Stone, J. L., Visscher, P. M., O'Donovan, M. C., et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature, 460(7256), 748-752.
21. Javitt, D. C. (2007). Glutamate and schizophrenia: Phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. International Review of Neurobiology, 78, 69-108.
22. Javitt, D. C., Spencer, K. M., Thaker, G. K., Winterer, G, & Hajós, M. (2008). Neurophysiological biomarkers for drug development in schizophrenia. Nature Reviews Drug Discovery, 7(1), 68-83.
23. Javitt, D. C., & Zukin, S. R. (1991). Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry, 148(10), 1301-1308.
24. Jentsch, J. D., & Roth, R. H. (1999). The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology, 20(3), 201-225.
25. Kristiansen, L. V., Beneyto, M., Haroutunian, V., & Meador-Woodruff, J. H. (2006). Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Molecular Psychiatry, 11, 737-747.
26. Krystal, J. H., Karper, L. P., Seibyl, J. P., Freeman, G. K., Delaney, R., Bremner, J. D., et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry, 51(3), 199-214.
27. Labrie, V., Fukumura, R., Rastogi, A., Fick, L. J., Wang, W., Boutros, P. C., et al. (2009). Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Human Molecular Genetics, 18 (17), 3227-3243.
28. Lahti, A. C., Koffel, B., LaPorte, D., & Tamminga, C. A. (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia.. Neuropsychopharmacology, 13(1), 9-19.
29. Lahti, A. C., Weiler, M. A., Tamara Michaelidis, B. A., Parwani, A., & Tamminga, C. A. (2001). Effects of ketamine in normal and schizophrenic volunteers.. Neuropsychopharmacology, 25(4), 455-467.
30. Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., et al. (1996). Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences of the United States of America, 93(17), 9235-9240.
31. Li, Y., Erzurumlu, R. S., Chen, C., Jhaveri, S., & Tonegawa, S. (1994). Whisker-related neuronal patterns fail to develop in the trigeminal brainstem nuclei of NMDAR1 knockout mice. Cell, 76(3), 427-437.
32. Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., et al. (2008). Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends in Neurosciences, 31(5), 234-242.
33. Luby, E. D., Cohen, B. D., Rosenbaum, G., Gottlieb, J. S., & Kelley, R. (1959). Study of a new schizophrenomimetic drug; sernyl.. AMA Archives of Neurology and Psychiatry, 81(3), 363-369.
34. Millar, J. K., Wilson-Annan, J. C., Anderson, S., Christie, S., Taylor, M. S., Semple, C. A., et al. (2000). Disruption of two novel genes by a translocation co-segregating with schizophrenia. Human Molecular Genetics, 9(9), 1415-1423.
35. Miyakawa, T, Leiter, L. M., Gerber, D. J., Gainetdinov, R. R., Sotnikova, T. D., et al. (2003). Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 100(15), 8987-8992.
36. Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999). Mice with reducedNMDAreceptor expression display behaviors related to schizophrenia. Cell, 98(4), 427-436.
37. Monaghan, D. T., Bridges, R. J., & Cotman, C. W. (1989). The excitatory amino acid receptors: Their classes, pharmacology and distinct properties in the function of the central nervous system. Annual Review of Pharmacology and Toxicology, 29, 365-402.
38. Moy, S. S., Nadler, J. J., Perez, A., Barbaro, R. P., Johns, J. M., Magnuson, T. R., et al. (2004). Sociability and preference for social novelty in five inbred strains: An approach to assess autistic-like behavior in mice. Genes, Brain and Behavior, 3 (5), 287-302.
39. Nilsson, M., Waters, S., Waters, N., Carlsson, A., & Carlsson, M. L. (2001). A behavioural pattern analysis of hypoglutamatergic mice - effects of four different antipsychotic agents. Journal of Neural Transmission, 108(10), 1181-1196.
40. Pilowsky, L. S., Bressan, R. A., Stone, J. M., Erlandsson, K., Mulligan, R. S., Krystal, J. H., et al. (2006). First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Molecular Psychiatry, 11(2), 118-119.
41. Ramsey, A. J., Laakso, A., Cyr, M., Sotnikova, T. D., Salahpour, A., Medvedev, I. O., et al. (2008). Genetic NMDA receptor deficiency disrupts acute and chronic effects of cocaine but not amphetamine. Neuropsychopharmacology, 33(11), 2701-2714.
42. Siapas, A. G., Lubenov, E. V., & Wilson, M. A. (2005). Prefrontal phase locking to hippocampal theta oscillations. Neuron, 46(1), 141-151.
43. Sirota, A., Montgomery, S., Fujisawa, S., Isomura, Y., Zugaro, M., & Buzsaki, G. (2008). Entrainment of neocortical neurons and gamma oscillations by the hippocampal theta rhythm.. Neuron, 60(4), 683-697.
44. Stefansson, H., Sigurdsson, E., Steinthorsdottir, V., Bjornsdottir, S., Sigmundsson, T., Ghosh, S., et al. (2002). Neuregulin 1 and susceptibility to schizophrenia. American Journal of Human Genetics, 71(4), 877-892.
45. Walsh, T., McClellan, J. M., McCarthy, S. E., Addington, A. M., Pierce, S. B., Cooper, G. M., et al. (2008). Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia.. Science, 320(5875), 539-543.
46. Winterer, G., Ziller, M., Dorn, H., Frick, K., Mulert, C., Wuebben, Y., et al. (2000). Schizophrenia: Reduced signal-to-noise ratio and impaired phase-locking during information processing. Clinical Neurophysiology, 111(5), 837-849.
47. Yeragani, V. K., Cashmere, D., Miewald, J., Tancer, M., & Keshavan, M. S. (2006). Decreased coherence in higher frequency ranges (beta and gamma) between central and frontal EEG in patients with schizophrenia: A preliminary report. Psychiatry Research, 141(1), 53-60.